ATRC News and Press, AtriCure Inc. From 08/04/21

AtriCure (NASDAQ:ATRC): Q2 GAAP EPS of -$0.36 misses by $0.02. Revenue of $71.4M (+74.9% Y/Y) beats by $10.32M. Press Release For further details see: AtriCure EPS misses by $0.02, beats on revenue

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. “Our second quarter results were driven by outperformance across our bu...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41 st Annual Growth Conference. AtriCur...

AtriCure has seen renewed top line momentum again, accompanied by continued losses and ever-increasing expectations. Despite recent approvals, which fortify the growth potential, I am leaning cautious on the back of the valuation multiple inflation. At these valuations, I am still...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021. AtriCure will host a confere...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. Ms. Telman has spent over 20 years in senio...

AtriCure ([[ATRC]] +11.5%) is trading sharply higher today following its announcement of the FDA approval granted for EPi-Sense System to treat patients with long-standing persistent atrial fibrillation (Afib).Affecting an estimated 33M people worldwide, Afib raises the risk of stro...

Gainers: Galera Therapeutics (GRTX) +26%, Ocular Therapeutix (OCUL) +17%, Capricor Therapeutics (CAPR) +15%, AtriCure (ATRC) +12%, Atossa Therapeutics (ATOS) +14%.Losers: Adverum Biotechnologies (ADVM) -60%, Cara Therapeutics (CARA) -44%,...

FDA approval results in the only label of its kind for more than 3 million patients in the United States, significantly expanding AtriCure’s addressable market Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiven...

Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q1 2021 Earnings Call Apr 27, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: AtriCure Inc (ATRC) Q1 2021 Earnings Call Transcript